UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 40

Sortiert nach

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Annals of oncology, 2020-12, Vol.31 (12), p.1623-1649

2020

Volltextzugriff (PDF)

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

Annals of oncology, 2020-05, Vol.31 (5), p.590-598

2020

Volltextzugriff (PDF)

Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?

Annals of oncology, 2013-02, Vol.24 (2), p.283-291

2013

Volltextzugriff (PDF)

Inhibiting HSP90 to treat cancer: a strategy in evolution

Current molecular medicine, 2012-11, Vol.12 (9), p.1108

2012

Volltextzugriff (PDF)

1965 Patterns of care and relative effectiveness of aromatase inhibitors compared to tamoxifen in patients with early breast cancer: A multi-institutional study

European journal of cancer (1990), 2015-09, Vol.51, p.S322-S322

2015

Volltextzugriff (PDF)

1962 The use of trastuzumab in patients with early breast cancer: A multi-institutional study

European journal of cancer (1990), 2015-09, Vol.51, p.S320-S320

2015

Volltextzugriff (PDF)

1961 Variation in the chemotherapy use patterns for patients with stage I breast cancer: A multi-institutional study

European journal of cancer (1990), 2015-09, Vol.51, p.S320-S320

2015

Volltextzugriff (PDF)

Brain Metastases After Breast-conserving Therapy for Early-stage Breast Cancer: Incidence and Characteristics by Subtype

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S188-S188

2012

Volltextzugriff (PDF)

Lower-Dose Stereotactic Radiosurgery for Small Brain Metastases: Local Control and Toxicity

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.S320-S321

2014

Volltextzugriff (PDF)

Reevaluating the role of antibody–drug conjugates in the treatment of patients with brain metastases

Annals of oncology, 2020-10, Vol.31 (10), p.1279-1281

Lin, N.U.

2020

Volltextzugriff (PDF)

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

Annals of oncology, 2015-01, Vol.26 (1), p.113-119

2015

Volltextzugriff (PDF)

Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?

Annals of oncology, 2024-01, Vol.35 (1), p.10-14

2024

Volltextzugriff (PDF)

Expanding the role of systemic therapy for patients with active, HER2-positive breast cancer brain metastases

ESMO open, 2022-12, Vol.7 (6), p.100596-100596, Article 100596

Lin, N.U.

2022

Volltextzugriff (PDF)

Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

Annals of oncology, 2013-06, Vol.24 (6), p.1526-1533

2013

Volltextzugriff (PDF)

335TiP Open-label, multinational, multicenter, phase IIIb/IV study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer (HER2+ BC): DESTINY-Breast12

Annals of oncology, 2021-09, Vol.32, p.S512-S513

2021

Volltextzugriff (PDF)

How we treat HER2-positive brain metastases

ESMO open, 2021-10, Vol.6 (5), p.100256-100256, Article 100256

2021

Volltextzugriff (PDF)

475P Dynamics of TROP2 expression in triple-negative breast cancer

Annals of oncology, 2023-10, Vol.34, p.S380-S381

2023

Volltextzugriff (PDF)

484P Multi-platform characterization of HER2 expression in triple-negative breast cancer

Annals of oncology, 2023-10, Vol.34, p.S385-S385

2023

Volltextzugriff (PDF)

285P Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study

Annals of oncology, 2023-10, Vol.34, p.S298-S298

2023

Volltextzugriff (PDF)

382MO Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer

Annals of oncology, 2023-10, Vol.34, p.S338-S338

2023

Volltextzugriff (PDF)

Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases

Annals of oncology, 2020-09, Vol.31 (9), p.1231-1239

2020

Volltextzugriff (PDF)

Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?

Annals of oncology, 2022-03, Vol.33 (3), p.234-238

2022

Volltextzugriff (PDF)

1MO Prognostic and biologic significance of HER2-low expression in early breast cancer

Annals of oncology, 2022-05, Vol.33, p.S124-S124

2022

Volltextzugriff (PDF)

Leptomeningeal Disease in Breast Cancer: Pre-Treatment Prognostic Factors and Outcomes

International journal of radiation oncology, biology, physics, 2021-11, Vol.111 (3), p.e574-e575

2021

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(40)

Sprache

Englisch
(40)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Oncology
(16)
Humans
(15)
Breast Neoplasms - Drug Therapy
(11)
Female
(10)
Breast Cancer
(9)
Hematology, Oncology And Palliative Medicine
(5)
Lapatinib
(5)
Treatment Outcome
(5)
Tumors
(5)
Antineoplastic Agents
(4)
Biological And Medical Sciences
(4)
Breast Neoplasms - Genetics
(4)
Gynecology. Andrology. Obstetrics
(4)
Mammary Gland Diseases
(4)
Medical Sciences
(4)
Receptor, Erbb-2 - Metabolism
(4)
Trastuzumab
(4)
Ado-Trastuzumab Emtansine
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(21)
Esmo Open
(6)
European Journal Of Cancer
(3)
International Journal Of Radiation Oncology, Biology, Physics
(3)
Neuro-Oncology
(2)
Oncogene
(2)
Breast Cancer Research And Treatment
(1)
Breast Diseases
(1)
Current Molecular Medicine
(1)

4 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?

Inhibiting HSP90 to treat cancer: a strategy in evolution

1965 Patterns of care and relative effectiveness of aromatase inhibitors compared to tamoxifen in patients with early breast cancer: A multi-institutional study

1962 The use of trastuzumab in patients with early breast cancer: A multi-institutional study

1961 Variation in the chemotherapy use patterns for patients with stage I breast cancer: A multi-institutional study

Brain Metastases After Breast-conserving Therapy for Early-stage Breast Cancer: Incidence and Characteristics by Subtype

Lower-Dose Stereotactic Radiosurgery for Small Brain Metastases: Local Control and Toxicity

Reevaluating the role of antibody–drug conjugates in the treatment of patients with brain metastases

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?

Expanding the role of systemic therapy for patients with active, HER2-positive breast cancer brain metastases

Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

335TiP Open-label, multinational, multicenter, phase IIIb/IV study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer (HER2+ BC): DESTINY-Breast12

How we treat HER2-positive brain metastases

475P Dynamics of TROP2 expression in triple-negative breast cancer

484P Multi-platform characterization of HER2 expression in triple-negative breast cancer

285P Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study

382MO Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer

Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases

Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?

1MO Prognostic and biologic significance of HER2-low expression in early breast cancer

Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022

Leptomeningeal Disease in Breast Cancer: Pre-Treatment Prognostic Factors and Outcomes

Suchergebnisse filtern